Safety and efficacy of sacubitril/valsartan vs. benazepril administered as initial treatment for STEMI patients with mid-range ejection fraction: a propensity score matching analysis - Summary - MDSpire
Advertisement
Safety and efficacy of sacubitril/valsartan vs. benazepril administered as initial treatment for STEMI patients with mid-range ejection fraction: a propensity score matching analysis
To assess the safety and efficacy of initial treatment with sacubitril/valsartan (S/V) in STEMI patients with mid-range left ventricular ejection fraction (LVEF, 40%–49%) during the study period from January 2019 to January 2025.
Key Findings:
After PSM, 35 patients were included in each matched group with well-balanced baseline characteristics.
The S/V group showed a significantly greater reduction in left ventricular end-systolic volume (LVESV) and improvements in left ventricular ejection fraction (LVEF) and left ventricular global longitudinal strain (GLS) compared to the benazepril group (all P <…
No significant differences in the incidence of major adverse cardiac events (MACE) or safety endpoints between the groups (all P > 0.05).
Interpretation:
Initial treatment with sacubitril/valsartan showed superior efficacy in improving short-term cardiac systolic function compared to benazepril in STEMI patients with mid-range LVEF, while both treatments had comparable safety profiles.
Limitations:
The study is retrospective and may have inherent biases.
The sample size is relatively small, necessitating validation in larger studies.
Conclusion:
These preliminary findings suggest that S/V may improve short-term cardiac function in STEMI patients with mid-range LVEF, but further research is needed to confirm long-term clinical outcomes.
